Joanna Parkinson

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Drug Administration

Cardiovascular Risk Factors

Heart Rate Variability

Top Venues

British journal of clinical pharmacology

Diabetes, obesity & metabolism

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology research & perspectives 12 (2) (2024)
Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology research & perspectives 12 (2) (2024)
Johanna Melin, Joanna Parkinson, Bengt Hamrén, Robert C Penland, David W Boulton, Weifeng Tang
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus. British journal of clinical pharmacology (2023)
Joanna Parkinson, Corina Dota, Christian Källgren, Christer Gottfridsson, Magnus Bjursell, Shira Perl, Thomas Kӧrnicke, Dinko Rekić, Susanne Johansson
Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling. British journal of clinical pharmacology (2022)
Joanna Parkinson, Corina Dota, Christian Källgren, Christer Gottfridsson, Magnus Bjursell, Shira Perl, Thomas Kӧrnicke, Dinko Rekić, Susanne Johansson
Verinurad does not prolong QTc interval: A thorough QT study using concentration-QTc modelling. British journal of clinical pharmacology (2022)
Veronika Voronova, Marie Cullberg, Philip Delff, Joanna Parkinson, Corina Dota, Gaia Schiavon, Brijesh Maroj, Dinko Rekić, S Y Amy Cheung
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. British journal of clinical pharmacology (2021)
Millie Shah, Leonid A Stolbov, Tatiana Yakovleva, Weifeng Tang, Victor Sokolov, Robert C Penland, David W Boulton, Joanna Parkinson
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, obesity & metabolism 23 (4) (2021)
Gael Cantet, Alienor Berges, Rhianna O'Sullivan, Sarit Cohen-Rabbie, Corina Dota, Vincent Dubois, Guillemette E Benoist, Helen Tomkinson, Dinko Rekić, Joanna Parkinson, Stein Schalkwijk
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance. British journal of clinical pharmacology (2021)
Joanna Parkinson, Weifeng Tang, Magnus Åstrand, Johanna Melin, Ella Ekholm, Bengt Hamrén, David W Boulton
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (6) (2019)
David Busse, Weifeng Tang, Markus Scheerer, Thomas Danne, Torben Biester, Viktor Sokolov, David Boulton, Joanna Parkinson
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. British journal of clinical pharmacology 85 (8) (2019)
Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W Boulton, Robert C Penland, Weifeng Tang
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (4) (2018)